# Pfizer signs Enodia Therapeutics deal on Sec61 small-molecule drugs

Canonical page: https://technooptimist.io/stories/pfizer-signs-enodia-therapeutics-deal-on-sec61-small-molecule-drugs-68672e82
Date: 13 Oct 2026
About: [Pfizer](https://technooptimist.io/companies/pfizer.md)
Original source: https://via.tt.se/pressmeddelande/4594181/enodia-therapeutics-announces-research-collaboration-and-license-agreement-with-pfizer-to-develop-sec61-targeting-small-molecules?lang=en

Pfizer has signed a research collaboration and license agreement with Enodia Therapeutics to discover and develop small-molecule Sec61 inhibitors. Enodia runs the discovery work against several collaboration targets; after the collaboration term, Pfizer takes over clinical, manufacturing, regulatory and commercial work.

## Key facts

- Enodia receives an upfront payment, amount not disclosed, plus research, development and sales milestones and tiered royalties on net sales; none of these amounts were disclosed.
- The announcement states a total potential value of more than $500 million.
- Enodia's approach is selective Sec61 translocon modulation, aiming to stop disease-driving proteins at the point of synthesis.
- Enodia says its platform spans several Sec61 inhibitor families and uses proteomics, cryo-EM and machine learning in molecule design.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.